Luminus Management’s Moderna MRNA Stock Holding History

Luminus Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-693,832	Closed	-$10.2M	–	116
2019 Q2	$10.2M	Buy	+693,832	New	+$14.9M	0.24%	71

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

RWA

Ropes Wealth Advisors Boston, Massachusetts $515M AUM 21.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Luminus Management's MRNA Position: Q3 2019 in Review

Luminus Management sold out of Moderna (MRNA) in Q3 2019, closing a stake of 693,832 shares — an estimated $10.2M sold.

Luminus Management first reported a position in MRNA in Q2 2019 and held it in 1 quarter. The position peaked at $10.2M in Q2 2019. 136 funds tracked by Wall St. Rank hold MRNA as of Q3 2019.

Luminus Management reported no remaining Moderna position as of Q3 2019 after selling out during the quarter.
Luminus Management sold 693,832 Moderna shares in Q3 2019, an estimated $10.2M.
Luminus Management first reported a position in Moderna in Q2 2019 and held it in 1 quarter.
Luminus Management's Moderna position peaked at $10.2M in Q2 2019.
136 funds tracked by Wall St. Rank held Moderna as of Q3 2019.

Based on Luminus Management's 13F filing for Q3 2019, filed 14 Nov 2019.